September was a reasonably mixed month for the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO). Although it finished the month more or less flat, several popular shares on the index such as TPG Telecom Ltd (ASX: TPM) fell heavily during the month and have yet to recover.
If your portfolio took a bit of a hit, I believe the following three growth shares could be just what it needs to give it a lift again.
Bellamy's Australia Ltd (ASX: BAL)
In August Bellamy's shares climbed around 12% after reporting a whopping 322% increase in net profit after tax to $38.3 million. But since then it has been nothing but down for its shares, much to the dismay of shareholders. Following a 3% decline today, this organic infant formula producer's shares are now down around 17% from their post-earnings high. At just 17x estimated FY 2017 earnings I believe Bellamy's is great value at the moment. Thanks to the big improvement in its margins and the insatiable demand from Chinese consumers, I believe the company will deliver on the market's strong growth expectations. All being well this should be the catalyst to taking the share price higher again.
iSentia Group Ltd (ASX: ISD)
Media monitoring company iSentia is another company which posted impressive full year results recently. Due to the strong growth of its Asia/Rest of the World segment and a better-than-expected performance from its recently acquired King Content business, iSentia reported a 23.6% rise in full-year net profit after tax to $24.3 million. According to CommSec analysts are currently forecasting this strong performance to continue. Analysts have forecast earnings to grow at an average of 32.5% per annum through to at least FY 2018. So with its shares changing hands at 21x estimated FY 2017 earnings, I believe iSentia is reasonably good value at this point.
Nanosonics Ltd. (ASX: NAN)
Nanosonics' trophon EPR ultrasound probe disinfector is what attracts me to the infection control solutions provider. According to the company, clinical studies have shown that the toxic liquid disinfectants currently being used in high level disinfectant ultrasound probes are wholly ineffective against human papillomavirus, whereas the company's trophon technology is completely effective. The growing popularity of its trophon technology not only meant the company recently reported a 93% jump in full year sales to $42.8 million, but it has also helped it win a 22% share of the North American market in a short space of time. Its shares are a little on the expensive side though at 23x sales, so it may be prudent to limit any investment to just a small part of your portfolio.
